RxDoctor Payments Data

Kimberly Ruszczyk, NP

Family · Syracuse, NYNPI 1508419409

Payments from drug & device makers

$1,953in general payments, 2019–2025

Across 98 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$547
  • Collegium Pharmaceutical, Inc.$494
  • Boston Scientific$332
  • Relievant Medsystems, Inc.$95
  • Lundbeck LLC$85
  • Vertex$65
  • plus $335 from 15 others

What the payments were for

  • Food & beverage$1,953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,953 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$60,236
Medicare patients
303
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate46$20,169
OxycontinOxycodone Hcl25$13,274
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen485$8,971
Gabapentin589$7,648
Fentanyl62$7,175
Hydromorphone ErHydromorphone Hcl24$5,981
Pregabalin177$4,673
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen252$4,474
Morphine Sulfate ErMorphine Sulfate135$3,438
Oxycodone Hcl239$2,625
Lidocaine28$2,364
Morphine Sulfate103$2,312
Celecoxib68$2,306
Tizanidine Hcl219$1,874
Naloxone Hcl24$1,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$494$20,16946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →